Yes, patients with ESRD are definitively considered immunocompromised.
Patients with end-stage renal disease should be managed as immunocompromised hosts, requiring specific vaccination protocols and heightened infection surveillance. The 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host explicitly categorizes ESRD patients within this framework, recommending they receive immunocompromised-specific vaccination schedules including PCV13 for pneumococcal disease 1.
Evidence Supporting Immunocompromised Status
Guideline-Based Classification
The IDSA guidelines treat ESRD patients as immunocompromised by:
- Recommending annual influenza vaccination due to severe disease risk in "end-stage organ disease" 1
- Noting that "patients awaiting transplant are at increased risk for invasive pneumococcal disease" and should receive PCV13 per CDC ACIP recommendations for immunocompromised persons 1
- Documenting impaired vaccine responses: fewer than 50% of chronic kidney disease patients maintain protective tetanus titers, and HepB vaccination is significantly less effective in hemodialysis patients, requiring high-dose (40 µg) formulations 1
Mechanistic Immune Dysfunction
The immunocompromised state in ESRD involves both innate and adaptive immune defects:
Adaptive immunity is severely impaired:
- B-cell and T-cell concentrations are reduced by 60% and 40% respectively compared to healthy controls 2
- S. aureus-specific IgG responses to key antigens (IsdB and Hla) are significantly lower at dialysis initiation 2
- T-helper cell responses remain impaired throughout the first year of hemodialysis 2
- Marked depletion of lymphoid lineages with widespread transcriptomic dysregulation 3
Innate immunity shows functional defects:
- Impaired oxidative burst activity persists throughout hemodialysis treatment 2
- S. aureus survival in whole blood is significantly higher in ESRD patients 2
- Downregulation of phagocyte adhesion molecules and opsonin receptors 4
Clinical Implications
Infection Risk and Outcomes
ESRD patients demonstrate:
- Higher CMV seropositivity (42.2% vs 22.2% in controls), with CMV-positive patients showing 77.3% prevalence of anemia 5
- Significantly higher Sequential Organ Failure Assessment (SOFA) scores and in-hospital mortality when developing sepsis 3
- Genetic variants predisposing to ESRD are associated with increased sepsis risk via Mendelian randomization analysis 3
Mortality Association
An "immuno-fragile profile" characterized by:
- Loss of naïve T cells
- Enrichment of effector memory T cells and non-classical monocytes
- This profile independently predicts all-cause mortality (HR 1.31) and cardiovascular mortality (HR 1.49) 6
Important Caveats
Paradoxical immune activation: ESRD presents with immunodeficiency coexisting with signs of immune system activation—increased production of IL-1, TNF-alpha, and IL-6 by activated monocytes 4. This "inflammaging syndrome" combines immunosenescence with chronic inflammation 7.
Dialysis effects: Hemodialysis accentuates rather than corrects immune dysregulation, particularly when using complement-activating membranes 4. However, some innate immunity markers (HLA-DR and CCR2 upregulation) show partial restoration during the first year of HD 2.
Treatment variability: Frailty and immune dysfunction vary by treatment modality, with hemodialysis patients showing the highest frailty prevalence (53%) and most pronounced immune alterations 8.